News Focus
News Focus
Followers 14
Posts 1561
Boards Moderated 0
Alias Born 02/27/2014

Re: jdc1 post# 20536

Tuesday, 10/27/2020 8:06:29 PM

Tuesday, October 27, 2020 8:06:29 PM

Post# of 44345
Below are the 4 remaining Analysts from September's Pre-Nasdaq Investor Call that have not yet initiated coverage. I think that all 4 might have something to say here.

1. Jim Birchenough with Wells Fargo

2. Madhu Kumar with Robert W. Baird

3. Kevin DeGeeter with Oppenheimer

4. Benjamin Burnett with Stifel Nicolaus


Plus the 4 from Jdc1's latest email that participated and have since initiated coverage so far:

Anthony Butler Roth Capital: October 1st 2020 - $25 price target
Joseph Pantginis H.C. Wainwright: October 14th 2020 - 31$ Price target
Louise Chen- Cantor Fitzgerald: October 21st 2020- $25 Price Target
Olga Smolentseva Bryan Garnier: October 22nd 2020 - $30 Price Target



Analyst Average of $27.75 represents a Market Cap of $1.4 Billion

HGEN is also participating in the upcoming conferences:

1. Roth Capital on 10/28
2. Bryan, Garnier & Co 11/16 & 11/17
3. Stifel on 11/17
4. Jefferies on 11/19


Phase III is near completion, EUA is on Tap and Company has already had a Type B Meeting with FDA in regarding submission plan for EUA & BLA.

NIH Sponsored "Big Effect Trail" ACTIV-5 is underway and already recruiting thru Emory University. This is a Double-blind, placebo-controlled study of 200 patients, NIH-sponsored, up to 40 US sites with Interim analysis planned at 50% enrollment. This should move very quickly.


Phew, HGEN has allot of things happening right now!


Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today